SCHEMBL14550488

SCHEMBL14550488

[2H]C([2H])([2H])NC(=O)c1cc(C)ccn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSA P10619 2/20 0.45
CSF1R P07333 1/20 0.42
FLT3 P36888 1/20 0.42
GRM5 P41594 1/20 0.41
FDPS P14324 1/20 0.41
ALKBH2 Q6NS38 4/20 0.40
ALKBH3 Q96Q83 4/20 0.40
FTO Q9C0B1 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
ALKBH5 Q6P6C2 2/20 0.40
PKM P14618 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
UHRF1 Q96T88 1/20 0.39
CCR1 P32246 1/20 0.39
CCR5 P51681 1/20 0.39
CCR8 P51685 1/20 0.39
PYGL P06737 1/20 0.39
PYGM P11217 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171083 0.87 CTSA (0.48) CTSACSF1RFLT3GRM5FDPS
SCHEMBL29580736 0.87 CTSA (0.48) CTSACSF1RFLT3GRM5FDPS
SCHEMBL14480939 0.81 KDM4C (0.57) GRM5NPC1RAB9APYGLPYGM
SCHEMBL107759 0.79 CTSA (0.50) CTSACSF1RFLT3GRM5FDPS
SCHEMBL30275603 0.77 TYK2 (0.45) FDPSNPC1RAB9APKMSMN1; SMN2
SCHEMBL10274536 0.76 KMT2A (0.50) CTSACSF1RFLT3NPC1RAB9A
SCHEMBL8486170 0.76 CTSA (0.54) CTSACSF1RFLT3GRM5FDPS
SCHEMBL346168 0.76 ANO1 (0.58) CSF1RFLT3
SCHEMBL14574955 0.75 ALDH1A1 (0.55) NPC1RAB9APKMSMN1; SMN2
SCHEMBL13852609 0.75 KMT2A (0.52) CTSAGRM5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669369-B2 Method and process for preparation and production of deuterated Ω-diphenylurea SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) 2014-03-11 US disclosed
US-20130060043-A1 PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD (CN) 2013-03-07 US disclosed
US-20130035492-A1 METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. 2013-02-07 US disclosed
US-20130018209-A1 PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) 2013-01-17 US disclosed
US-20130012548-A1 DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) 2013-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130060043-A1 PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA CCND3, UBE2D3, VDR CTSA 2538/4885CSF1R 4714/4885FLT3 2441/4885
US-20130012548-A1 DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS PPARD, HDHD5, SCD CTSA 1348/4885CSF1R 4495/4885FLT3 559/4885
US-20130035492-A1 METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA PNLIP, PDXK, PNP CTSA 3017/4885CSF1R 4755/4885FLT3 2261/4885
US-20130018209-A1 PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF NSD3, CCND3, DRD3 CTSA 4882/4885CSF1R 3403/4885FLT3 3002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.